sars-cov-2 mrna vaccine
Vaccineexperimental
Clinical trial activity
5 trials · 10 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
1
Phase 4
0
Earliest trial started Jul 22, 2021 (NCT04847102)
Timeline
Indications
Studied for
Mechanism of action
- Spike glycoproteinImmunity, active
Spike glycoprotein immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06680375 | Phase 2 | Nov 11, 2024 | GlaxoSmithKline |
| NCT05599802 | Phase 1 | Feb 28, 2023 | AIM Therapeutics Inc., Government of China, University of Karachi |
| NCT05492643 | N/A | Aug 13, 2022 | Wuhan University, Xiamen University |
| NCT05272605 | Phase 1 | Apr 5, 2022 | Southern Star Research Pty Ltd., University of Melbourne |
| NCT04847102 | Phase 3 | Jul 22, 2021 | Abogen Biosciences Co. Ltd., Walvax Biotechnology Co., Ltd. |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (10)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Abogen Biosciences Co. Ltd. | For profit | 1 | 0 | 1 | 2021 |
| AIM Therapeutics Inc. | For profit | 1 | 0 | 1 | 2023 |
| GlaxoSmithKline | For profit | 1 | 1 | 1 | 2024 |
| Government of China | Government | 1 | 1 | 1 | 2023 |
| Southern Star Research Pty Ltd. | For profit | 1 | 0 | 1 | 2022 |
| University of Karachi | Academic/Hospital | 1 | 0 | 1 | 2023 |
| University of Melbourne | Academic/Hospital | 1 | 1 | 1 | 2022 |
| Walvax Biotechnology Co., Ltd. | For profit | 1 | 1 | 1 | 2021 |
| Wuhan University | Academic/Hospital | 1 | 0 | 1 | 2022 |
| Xiamen University | Academic/Hospital | 1 | 1 | 1 | 2022 |
10 organizations
Page 1 / 1